FDA approves Ionis' DAWNZERA (donidalorsen) for HAE prophylaxis in patients 12+

IONIS PHARMACEUTICALS INC

First and only RNA-targeted HAE medicine; self-administered every 4 or 8 weeks via autoinjector.
Phase 3 OASIS-HAE: Q4W reduced monthly attack rate 81% vs placebo (primary endpoint); 87% from second dose.
OASISplus OLE: 94% attack rate reduction after one year; switch cohort reduced attacks 62% vs prior therapy.
Ionis' second independent launch in nine months; 84% of patients surveyed preferred DAWNZERA over prior treatment.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.